胰岛素带来的启示:实现糖尿病和肥胖药物可负担的政策处方
文章回顾了美国为改善胰岛素可负担性而提出或实施的系列政策,包括自付费用上限、针对涨价药物的返利要求、政府药价谈判、促进竞争及公共生产等,并讨论这些政策对糖尿病和肥胖治疗药物的启示,认为实现可负担与公平可及需要多方综合施策。
要点
- 州和联邦立法已为部分患者设定胰岛素自付费用上限。
- 返利要求和政府药价谈判可能抑制现有药物涨价,但或无意中鼓励新药提高上市价格。
- 促进竞争、减少生物类似药准入障碍及公共生产是改善可负担性的其他政策路径。
核心结论
- 实现胰岛素及其他糖尿病和肥胖药物的可负担与公平可及需要多层面方法,涉及州和联邦干预、持续政策评估与完善,以及对医疗保健中企业影响的批判性审视。
研究设计与样本
- 本文为政策综述,梳理了已提出或实施的改善胰岛素可负担性的政策及其对其他糖尿病和肥胖治疗药物的启示。
主要发现
- 州和联邦立法已为部分患者设定胰岛素自付费用上限。
- 针对涨价超过通胀率的药物要求返利的立法可能抑制现有药物的价格上涨。
- 2022年《通货膨胀削减法案》允许对某些高支出且无仿制药或生物类似药竞争的药物进行有限谈判,包括部分胰岛素产品和其他糖尿病药物。
- 有人担心药价谈判可能无意中鼓励新药设定更高的上市价格。
- 加州CalRx项目旨在以显著降低的价格提供生物类似药胰岛素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Escalating insulin prices have prompted public scrutiny of the practices of drug manufacturers, pharmacy benefit managers, health insurers, and pharmacies involved in production and distribution of medications. As a result, a series of policies have been proposed or enacted to improve insulin affordability and foster greater equity in access. These policies have implications for other diabetes and obesity therapeutics. Recent legislation, at both the state and federal level, has capped insulin out-of-pocket payments for some patients. Other legislation has targeted drug manufacturers directly in requiring rebates on drugs with price increases beyond inflation rates, an approach that may restrain price hikes for existing medications. In addition, government negotiation of drug pricing, a contentious issue, has gained traction, with the Inflation Reduction Act of 2022 permitting limited negotiation for certain high expenditure drugs without generic or biosimilar competition, including some insulin products and other diabetes medications. However, concerns persist that this may inadvertently encourage higher launch prices for new medications. Addressing barriers to competition has also been a priority such as through increased enforcement against anticompetitive practices (e.g., "product hopping") and reduced regulatory requirements for biosimilar development and market entry. A novel approach involves public production, exemplified by California's CalRx program, which aims to provide biosimilar insulins at significantly reduced prices. Achieving affordable and equitable access to insulin and other diabetes and obesity medications requires a multifaceted approach, involving state and federal intervention, ongoing policy evaluation and refinement, and critical examination of corporate influences in health care.
引用
- Nagel KE, Ramachandran R, Lipska KJ, et al. Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications. Diabetes Care. 2024. PMID: 38536964. doi:10.2337/dci23-0042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。